Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Topics in Pharmacology   Volumes    Volume 11  Issue 1
Long term effects of dilazep hydrochloride, an anti-platelet drug, on patients with IgA nephropathy - Reports of 5-year treatment
Yasuhiko Tomino
Pages: 45 - 49
Number of pages: 5
Current Topics in Pharmacology
Volume 11  Issue 1

Copyright © 2007 Research Trends. All rights reserved

It is important to start treatment from an early stage of IgA nephropathy although there is still no specific treatment at present. Surveillance of long-term 5-year treatment with dilazep hydrochloride (Comerian), an anti-platelet drug, in 106 patients with IgA nephropathy was conducted at 52 clinical sites in the Tokyo area of Japan. Results obtained in the present study were as follows: 1) 106 patients who received dilazep hydrochloride for 5 years or lomger were either in the relatively good prognosis group or in the relatively poor prognosis group. 2) Urinary protein excretion was decreased: 35.1% of the patients were considered “improved” and 54.5% were “slightly improved or better”. 3) Creatinine clearance (CCr) was not significantly changed with a low improvement rate: 3.5% of the patients were considered “improved” and 10.5% were “slightly improved or better”, but fewer patients were judged “aggravated”(17.5%). 4) Favorable improvement effects on erythrocytes in urine were observed: 22.6% of the patients were considered “improved” and 50.0% were “slightly improved or better”. 5) Leukocytes increased as an adverse drug reaction in one patient (0.9%). These results showed that dilazep hydrocholide is safe and well tolerated in long-term treatment, and has a beneficial effect on several urinary findings, indicating that it is effective in maintaining renal function. Therefore, dilazep hydrochloride can be considered as the first line drug for patients with IgA nephropathy, in whom only relatively-mild tissue damage and comparatively stable progress are observed.
Buy this Article


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms